The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cosciens Biopharma's Revenue for the
three
months ended in Mar. 2026 was $1.89 Mil. Cosciens Biopharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1.54 Mil.
Hence, Cosciens Biopharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.23.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Cosciens Biopharma Receivables Turnover Related Terms
Cosciens Biopharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCIF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCIF) has a Receivables Turnover of 1.23 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cosciens Biopharma and its competitors. According to the industry distribution chart, Cosciens Biopharma ranks #523 out of 845 companies in the Biotechnology industry, placing it in the top 61.9%.
Is Cosciens Biopharma's Receivables Turnover too high?
Cosciens Biopharma's current Receivables Turnover is 1.23. The Biotechnology industry median Receivables Turnover is 5.28. Cosciens Biopharma's value of 1.23 is 76.7% below this industry median. Based on the distribution chart, Cosciens Biopharma ranks #523 out of 845 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #523 out of 845 companies for Receivables Turnover. This places Cosciens Biopharma in the lower half of its industry. The industry median Receivables Turnover is 5.28. Cosciens Biopharma's value of 1.23 is 76.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosciens Biopharma's current Receivables Turnover of 1.23 is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Cosciens Biopharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosciens Biopharma's current Receivables Turnover is 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Fairly Valued. The stock's GF Value™ is $2.34, compared to a current price of $2.30 — trading 1.7% below its estimated fair value. The current Receivables Turnover is 1.23 and 76.7% below the Biotechnology industry median of 5.28. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Receivables Turnover is 1.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $2.30 is trading 1.7% below its estimated GF Value™ of $2.34.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCIF:
Receivables Turnover: 1.23
GF Value™: $2.34 vs. price of $2.30 (1.7% below fair value)
Industry Position: 76.7% below the Biotechnology median (#523 of 845)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCIF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
